Skip to main content

Advertisement

Table 2 Patient and treatment characteristics for the patients with recurrence

From: Assessment and topographic characterization of locoregional recurrences in head and neck tumours

Primary tumour site Stage Type RT Type CH Dpresc/Gy/#fx Ddeliv CTV-T/Gy RT tech Recurrence location Diagn./months Rec vol./cm3
Oral cavity (tongue) III Adjuvant (Post-op)   59.1/30 59.0 3DCRT Mobile Tongue + Cervical 6.7 2.0 + 27.6
Oral cavity (mand. gingivae) IVA Adjuvant (Post-op)   59.4/31 58.7 dIMRT Mandibular gingivae 7.8 7.0
Oral cavity (tongue) IVA Adjuvant (Post-op)   59.0/31 59.8 dIMRT Cervical 9.0 27.1
Oral cavity (hard palate) IVA Concomitant Cisplatin 70.2/39 70.2 3DCRT Pharynx + Cervical 8.5 16.6 + 82.2
Oral cavity (max. gingivae) IVA Concomitant (Post-op) Cisplatin 64.8/36 65.3 rIMRT Maxillary gingivae 8.7 9.9
Oropharynx (tonsil) II Intensive   70.2/33 69.8 rIMRT Tonsil 22.8 clinical
Oropharynx (tonsil) IVA Adjuvant (Post-op)   59.4/33 57.0 (pb) dIMRT Base tongue 21.1 4.0
Oropharynx (base tongue) IVA Sequential TPF 69.3/33 69.2 rIMRT Base tongue 9.8 36.6
Oropharynx (base tongue) IVA Sequential TPF 70.2/39 68.1 (pb) dIMRT Cervical 31.2 17.1
Oropharynx (base tongue) IVA Concomitant Cisplatin 69.6/33 68.7 IMRT Tonsil + Cervical + Submandid. 7.3 0.4 + 0.5 + 2.7
Hypopharynx (pyriform sinus) IVA Concomitant (Post-op) Cisplatin 64.8/33 56.9/29* rIMRT Posterior wall + Cervical 9.8 10.3 + 24.1
Hypopharynx (posterior wall) IVA Intensive   69.0/33 68.0 rIMRT Cervical 15.4 0.6 + 1.0
Hypopharynx (pyriform sinus) IVA Sequential PF 70.2/39 67.7 (pb) dIMRT Cervical 26.7 0.3
Hypopharynx (pyriform sinus) IVA Sequential PF 70.2/39 70.1 rIMRT Pyriform sinus 9.6 8.0
Hypopharynx (pyriform sinus) IVB Sequential TPF 70.2/39 72.4 (pb) dIMRT Cervical 23.7 15.2
Larynx (glottis) I Intensive   66/33 65.9 3DCRT Larynx 12.4 14.8
Larynx (glottis) II Intensive   70.0/35 69.9 3DCRT Larynx 9.2 19.4
Larynx (supraglottis) IVA Concomitant Cisplatin 70.2/39 69.4 (pb) dIMRT Larynx 32.6 1.3
Larynx (supraglottis) IVA Concomitant (Post-op) Cisplatin 64.8/36 62.6/35* dIMRT Glottis 8.8 1.7
Nasopharynx IIB Intensive   70.2/39 69.4 rIMRT Cervical 16.0 2.7
Nasopharynx IVB Concomitant Cisplatin 70.2/33 75.9 (pb) IMRT Right orbit 34.4 11.9
Pharyngeal-laryngeal IVA Adjuvant (Post-op)   59.4/33 59.7 dIMRT Peritracheostomy + Cervical 25.5 0.5 + 44.0
  1. Dpresc and Ddeliv is the prescribed dose and the mean dose delivered to the primary tumour corrected for incomplete treatment delivery and recalculated with the collapsed-cone dose algorithm.
  2. *Failure to complete prescribed treatment, (pb) refers to the dose calculation algorithm used for treatment planning.